125 related articles for article (PubMed ID: 10615894)
1. Abeta42-positive non-pyramidal neurons around amyloid plaques in Alzheimer's disease.
Mochizuki A; Tamaoka A; Shimohata A; Komatsuzaki Y; Shoji S
Lancet; 2000 Jan; 355(9197):42-3. PubMed ID: 10615894
[TBL] [Abstract][Full Text] [Related]
2. Non-toxic conformer of amyloid β may suppress amyloid β-induced toxicity in rat primary neurons: implications for a novel therapeutic strategy for Alzheimer's disease.
Izuo N; Murakami K; Sato M; Iwasaki M; Izumi Y; Shimizu T; Akaike A; Irie K; Kume T
Biochem Biophys Res Commun; 2013 Aug; 438(1):1-5. PubMed ID: 23747423
[TBL] [Abstract][Full Text] [Related]
3. Plasma antibodies to Abeta40 and Abeta42 in patients with Alzheimer's disease and normal controls.
Xu W; Kawarabayashi T; Matsubara E; Deguchi K; Murakami T; Harigaya Y; Ikeda M; Amari M; Kuwano R; Abe K; Shoji M
Brain Res; 2008 Jul; 1219():169-79. PubMed ID: 18534566
[TBL] [Abstract][Full Text] [Related]
4. Amyloid beta-peptide levels in laser capture microdissected cornu ammonis 1 pyramidal neurons of Alzheimer's brain.
Aoki M; Volkmann I; Tjernberg LO; Winblad B; Bogdanovic N
Neuroreport; 2008 Jul; 19(11):1085-9. PubMed ID: 18596605
[TBL] [Abstract][Full Text] [Related]
5. Amyloid beta peptide 1-42 highly correlates with capillary cerebral amyloid angiopathy and Alzheimer disease pathology.
Attems J; Lintner F; Jellinger KA
Acta Neuropathol; 2004 Apr; 107(4):283-91. PubMed ID: 14986026
[TBL] [Abstract][Full Text] [Related]
6. Passive immunization of the Abeta42(43) C-terminal-specific antibody BC05 in a mouse model of Alzheimer's disease.
Asami-Odaka A; Obayashi-Adachi Y; Matsumoto Y; Takahashi H; Fukumoto H; Horiguchi T; Suzuki N; Shoji M
Neurodegener Dis; 2005; 2(1):36-43. PubMed ID: 16909001
[TBL] [Abstract][Full Text] [Related]
7. Intracellular Abeta42 activates p53 promoter: a pathway to neurodegeneration in Alzheimer's disease.
Ohyagi Y; Asahara H; Chui DH; Tsuruta Y; Sakae N; Miyoshi K; Yamada T; Kikuchi H; Taniwaki T; Murai H; Ikezoe K; Furuya H; Kawarabayashi T; Shoji M; Checler F; Iwaki T; Makifuchi T; Takeda K; Kira J; Tabira T
FASEB J; 2005 Feb; 19(2):255-7. PubMed ID: 15548589
[TBL] [Abstract][Full Text] [Related]
8. Abeta peptides can enter the brain through a defective blood-brain barrier and bind selectively to neurons.
Clifford PM; Zarrabi S; Siu G; Kinsler KJ; Kosciuk MC; Venkataraman V; D'Andrea MR; Dinsmore S; Nagele RG
Brain Res; 2007 Apr; 1142():223-36. PubMed ID: 17306234
[TBL] [Abstract][Full Text] [Related]
9. Biochemical stages of amyloid-β peptide aggregation and accumulation in the human brain and their association with symptomatic and pathologically preclinical Alzheimer's disease.
Rijal Upadhaya A; Kosterin I; Kumar S; von Arnim CA; Yamaguchi H; Fändrich M; Walter J; Thal DR
Brain; 2014 Mar; 137(Pt 3):887-903. PubMed ID: 24519982
[TBL] [Abstract][Full Text] [Related]
10. Consistent immunohistochemical detection of intracellular beta-amyloid42 in pyramidal neurons of Alzheimer's disease entorhinal cortex.
D'Andrea MR; Nagele RG; Wang HY; Lee DH
Neurosci Lett; 2002 Nov; 333(3):163-6. PubMed ID: 12429373
[TBL] [Abstract][Full Text] [Related]
11. Consequence of Abeta immunization on the vasculature of human Alzheimer's disease brain.
Boche D; Zotova E; Weller RO; Love S; Neal JW; Pickering RM; Wilkinson D; Holmes C; Nicoll JA
Brain; 2008 Dec; 131(Pt 12):3299-310. PubMed ID: 18953056
[TBL] [Abstract][Full Text] [Related]
12. Aβ38 in the brains of patients with sporadic and familial Alzheimer's disease and transgenic mouse models.
Reinert J; Martens H; Huettenrauch M; Kolbow T; Lannfelt L; Ingelsson M; Paetau A; Verkkoniemi-Ahola A; Bayer TA; Wirths O
J Alzheimers Dis; 2014; 39(4):871-81. PubMed ID: 24305500
[TBL] [Abstract][Full Text] [Related]
13. The coexistence of an equal amount of Alzheimer's amyloid-β 40 and 42 forms structurally stable and toxic oligomers through a distinct pathway.
Chang YJ; Chen YR
FEBS J; 2014 Jun; 281(11):2674-87. PubMed ID: 24720730
[TBL] [Abstract][Full Text] [Related]
14. Inositol trisphosphate 3-kinase B is increased in human Alzheimer brain and exacerbates mouse Alzheimer pathology.
Stygelbout V; Leroy K; Pouillon V; Ando K; D'Amico E; Jia Y; Luo HR; Duyckaerts C; Erneux C; Schurmans S; Brion JP
Brain; 2014 Feb; 137(Pt 2):537-52. PubMed ID: 24401760
[TBL] [Abstract][Full Text] [Related]
15. Cytoplasmic cytochrome c immunolabelling in dystrophic neurites in Alzheimer's disease.
Woodhouse A; Vickers JC; Dickson TC
Acta Neuropathol; 2006 Oct; 112(4):429-37. PubMed ID: 16855832
[TBL] [Abstract][Full Text] [Related]
16. Intraneuronal amyloid beta42 enhanced by heating but counteracted by formic acid.
Ohyagi Y; Tsuruta Y; Motomura K; Miyoshi K; Kikuchi H; Iwaki T; Taniwaki T; Kira J
J Neurosci Methods; 2007 Jan; 159(1):134-8. PubMed ID: 16860394
[TBL] [Abstract][Full Text] [Related]
17. Tau protein immunoreactivity in dementia of the Alzheimer type. I. Morphology, evolution, distribution, and pathogenetic implications.
Papasozomenos SC
Lab Invest; 1989 Jan; 60(1):123-37. PubMed ID: 2492060
[TBL] [Abstract][Full Text] [Related]
18. Morphology and distribution of plaque and related deposits in the brains of Alzheimer's disease and control cases. An immunohistochemical study using amyloid beta-protein antibody.
Ikeda S; Allsop D; Glenner GG
Lab Invest; 1989 Jan; 60(1):113-22. PubMed ID: 2642985
[TBL] [Abstract][Full Text] [Related]
19. [Brain pathology in Alzheimer's disease. Progress in the immunohistochemistry study of amyloid senile plaques].
Ishii T
Nihon Rinsho; 1988 Jul; 46(7):1464-70. PubMed ID: 3065523
[No Abstract] [Full Text] [Related]
20. Abeta42-carboxy-terminal-like immunoreactivity is associated with intracellular neurofibrillary tangles and pick bodies.
Schwab C; McGeer PL
Exp Neurol; 2000 Feb; 161(2):527-34. PubMed ID: 10686074
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
